The explosive growth of Ozempic and other drugs known as GLP-1 agonists has led to greater recognition of obesity as a chronic condition rather than a lifestyle disease, sparking concerns about budget-busting costs.
A group of health care organizations launched the EveryBODY campaign pushing for comprehensive coverage of obesity care, citing 'misunderstandings' about obesity that led to insurance restrictions.
[
add
]
[
|
|
...
]